Our screens revealed that synergy between MDM2 inhibitors and PI3K pathway inhibitors, MEK inhibitors, BH3 mimetics, HDAC inhibitors, and dasatinib was far more prevalent than previously appreciated, occurring across multiple tumor cell types and genetic backgrounds. The gene discussed is MDM2; the disease is neoplasm.